Next Article in Journal
Antibodies against Anthrax: Mechanisms of Action and Clinical Applications
Previous Article in Journal
Llama-Derived Single Domain Antibodies Specific for Abrus Agglutinin
Previous Article in Special Issue
Molecular Conversion of Muscarinic Acetylcholine Receptor M5 to Muscarinic Toxin 7 (MT7)-Binding Protein
Toxins 2011, 3(11), 1420-1432; doi:10.3390/toxins3111420
Review

Pharmacological Aspects of Vipera xantina palestinae Venom

1
, 2
, 1
, 1
, 2
, 3
 and 1,*
Received: 14 September 2011; in revised form: 3 October 2011 / Accepted: 1 November 2011 / Published: 14 November 2011
(This article belongs to the Special Issue Snake Venoms)
View Full-Text   |   Download PDF [665 KB, uploaded 14 November 2011]   |   Browse Figures
Abstract: In Israel, Vipera xantina palestinae (V.x.p.) is the most common venomous snake, accounting for several hundred cases of envenomation in humans and domestic animals every year, with a mortality rate of 0.5 to 2%. In this review we will briefly address the research developments relevant to our present understanding of the structure and function of V.x.p. venom with emphasis on venom disintegrins. Venom proteomics indicated the presence of four families of pharmacologically active compounds: (i) neurotoxins; (ii) hemorrhagins; (iii) angioneurin growth factors; and (iv) different types of integrin inhibitors. Viperistatin, a α1β1selective KTS disintegrin and VP12, a α2β1 selective C-type lectin were discovered. These snake venom proteins represent promising tools for research and development of novel collagen receptor selective drugs. These discoveries are also relevant for future improvement of antivenom therapy towards V.x.p. envenomation.
Keywords: Vipera xantina palestinae; venom; neurotoxin; hemorrhagin; integrin inhibitors; antivenom Vipera xantina palestinae; venom; neurotoxin; hemorrhagin; integrin inhibitors; antivenom
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Momic, T.; Arlinghaus, F.T.; Arien-Zakay, H.; Katzhendler, J.; Eble, J.A.; Marcinkiewicz, C.; Lazarovici, P. Pharmacological Aspects of Vipera xantina palestinae Venom. Toxins 2011, 3, 1420-1432.

AMA Style

Momic T, Arlinghaus FT, Arien-Zakay H, Katzhendler J, Eble JA, Marcinkiewicz C, Lazarovici P. Pharmacological Aspects of Vipera xantina palestinae Venom. Toxins. 2011; 3(11):1420-1432.

Chicago/Turabian Style

Momic, Tatjana; Arlinghaus, Franziska T.; Arien-Zakay, Hadar; Katzhendler, Jeoshua; Eble, Johannes A.; Marcinkiewicz, Cezary; Lazarovici, Philip. 2011. "Pharmacological Aspects of Vipera xantina palestinae Venom." Toxins 3, no. 11: 1420-1432.


Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert